CoChat

Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial

Open access
Korthuis, Philip T., Lum, Paula J., Vergara‐Rodriguez, Pamela, Ahamad, Keith, Wood, Evan, Kunkel, Lynn E., Oden, Neal L., Lindblad, Robert, Sorensen, James L., Arenas, Virgilio, Ha, Doan, Mandler, Raul N., McCarty, Dennis, for the CTN‐0055 CHOICES Investigators · 2017 · Addiction
Cited by 61

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background and aims: HIV‐infected people with substance use disorders are least likely to benefit from advances in HIV treatment. Integration of extended‐release naltrexone (XR‐NTX) into HIV clinics may increase engagement in the HIV care continuum by decreasing substance use. We aimed to compare (1) XR‐NTX treatment initiation, (2) retention and (3) safety of XR‐NTX versus treatment as usual (TAU) for treating opioid use disorder (OUD) and/or alcohol use disorder (AUD) in HIV clinics. Design: Non‐blinded randomized trial of XR‐NTX versus pharmacotherapy TAU. Setting: HIV primary care clinics in Vancouver, BC, Canada and Chicago, IL, USA. Participants: Fifty‐one HIV‐infected patients seeking treatment for OUD (n = 16), AUD (n = 27) or both OUD and AUD (n = 8). Measurements: Primary outcomes were XR‐NTX initiation (receipt of first injection within 4 weeks of randomization) and retention at 16 weeks. Secondary outcomes generated point estimates for change in substance use, HIV viral suppression [HIV RNA polymerase chain reaction (pcr) < 200 copies/ml] and safety. Findings: Two‐thirds (68%) of participants assigned to XR‐NTX initiated treatment, and 88% of these were retained on XR‐NTX at 16 weeks. In comparison, 96% of TAU participants initiated treatment, but only 50% were retained on medication at 16 weeks. Mean days of opioid use in past 30 days decreased from 17.3 to 4.1 for TAU and from 20.3 to 7.7 for XR‐NTX. Mean heavy drinking days decreased from 15.6 to 5.7 for TAU and 12.5 to 2.8 for XR‐NTX. Among those with OUD, HIV suppression improved from 67 to 80% for XR‐NTX and 58 to 75% for TAU. XR‐NTX was well tolerated, with no precipitated withdrawals and one serious injection‐site reaction. Conclusions: Extended‐release naltrexone (XR‐NTX) is feasible and safe for treatment of opioid use disorder and alcohol use disorder in HIV clinics. Treatment initiation appears to be lower and retention greater for XR‐NTX compared with treatment as usual (clinicaltrials.gov NCT01908062).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/add.13753

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 61

Metadata

Authors
Korthuis, P. T., Lum, P. J., Vergara‐Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., McCarty, D., & for the CTN‐0055 CHOICES Investigators
Venue
Addiction
Publisher
Wiley
Published
2017-02-08
Volume
112
Issue
6
Pages
1036-1044
ISSN
  • 0965-2140 (ISSN-L)
  • 1360-0443
OpenAlex
W2567850197
Cited by
61
References
5
FWCI
6.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. https://app.cochat.ai/papers/10.1111/add.13753
The paper
Korthuis, P. T., Lum, P. J., Vergara‐Rodriguez, P., Ahamad, K., Wood, E., Kunkel, L. E., Oden, N. L., Lindblad, R., Sorensen, J. L., Arenas, V., Ha, D., Mandler, R. N., McCarty, D., & for the CTN‐0055 CHOICES Investigators. (2017). Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. https://doi.org/10.1111/add.13753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.